Experimental Details General considerations
All experiments were performed under an atmosphere of dry nitrogen using standard Schlenk-line and glovebox techniques, unless stated otherwise. Solvents were distilled under nitrogen over the appropriate drying agent; CaCl2 (DCM), benzophenone/NaK (Et2O, THF), LiAlH4 (pentane), K2CO3 (MeCN, acetone), P2O5 (CD2Cl2, CDCl3). C6D6 was dried over Na at room temperature. Anhydrous MeOH was obtained from Sigma-Aldrich. Water was degassed ultrasonically under reduced pressure. 2-Azido-phenyl isonitrile (1) 1 was kindly provided by C. A. Dumke and F. E. Hahn. 2 All other reagents were used as received. Solids were predried in vacuo for at least 15 min. NMR spectra were recorded on Bruker Avance 400 ( 1 H, 400.13 MHz; 13 C{ 1 H}, 100.61 MHz, room temperature) or a Bruker Avance 500 ( 1 H, 500.23 MHz; 13 C{ 1 H}, 125.78 MHz; room temperature) . Chemical shifts are reported in ppm downfield from tetramethylsilane. 1 H-spectra were internally referenced to residual solvent resonances: CDCl3 (δ 7.26) and CD2Cl2 (δ 5.32). 13 C-spectra were internally referenced to residual solvent resonances: CDCl3 (δ 77.16) and CD2Cl2 (δ 53.84) . Melting points were measured using a Büchi Melting Point M-565 (sealed capillaries) and are uncorrected. High resolution electrospray ionization (ESI) mass spectrometry was carried out using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 4500 V). Infrared spectra have been recorded on a Shimadzu FT-IR 8400S spectrophotometer.
(1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) dichloride dimer 3 Prepared according to literature procedures.
1,3-dimethyl-benzimidazolium iodide 4
Prepared according to literature procedures.
Bis(1,3-dimethylbenzimidazolidin-2-ylidene) 5
(2-azidophenylisonitrile) (1-methyl-4-isopropyl-benzene) ruthenium(II) dichloride 6
(2-azidophenylisonitrile) (1,2,3,4,5-pentamethylcyclopentadienyl) rhodium(III) dichloride [RhCp*Cl2] (94 mg, 0.15 mmol, 1.0 eq.) in DCM (15 mL) was added to 2-azidophenylisonitrile (49 mg, 0.34 mmol, 2.3 eq.) to provide a red solution, which was stirred for 43.5h at RT, in absence of light. Evaporation provided a red powder, which was washed with Et2O (3 x 10 mL) to provide [RhCp*(2-azidophenyl isonitrile)Cl2] as a red powder (107 mg, 0.24 mmol, 77.7%). [RhCp*(2-azidophenyl isonitrile)Cl2] was stored as a solid in absence of light at -20 °C. Mp: 324 °C ≤ decomp. 1 H NMR (500.23 MHz, CD2Cl2): δ = 7. 2H, o, 7.31 (d, 3 JH, H = 8.5 Hz, 1H, 7.21 (t, 3 JH,H = 7.6 Hz, 1H, p-Ar-H), 1.81 (s, 15H, Cp*-CH3). 13 MHz, CD2Cl2): δ = 138.0 (s, m-Ar-C-N3), 131.7 (s, 128.8 (s, 125.8 (s, 119.5 (s, , 101.1 (s, Cp*-CCH3), 9.7 Chem. Eur. J., 2003, 9, 704−712. 2 Michel, Inorg. Chem., 1990 , 29, 2023 −2025 . 4 B. Bostai, Z. Novák, A.C. Bényei, A. Kotschy, Org. Lett. 2007 
(1H-benzimidazolylidene) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) diiodide (4)
Alternative protocol 1: FeCl3 (27 mg, 0.165 mmol, 1.5 eq.) was dissolved in acetonitrile (12 mL) , after which NaI (150 mg, 1 mmol, 9.1 eq.) was added to provide a black suspension. Immediately afterwards, a solution of [(2-azidophenylisonitrile)IrCp*Cl2] (60 mg, 0.11 mmol, 1.0 eq.) in DCM (3 mL) was added to the black suspension and the resulting mixture was stirred for 4h at RT. Volatiles (including iodine) were removed in vacuo to provide a black residue, which was extracted in DCM (40 mL) under atmospheric conditions. The dark extract was subsequently washed with a solution of Na2S2O3 (100 mL, 20% in H2O) and NaHCO3 (100 mL, saturated solution in H2O). The resulting orange solution was dried over Na2SO4. After evaporation, [(1H-benzimidazolylidene)IrCp*I2] was obtained as a dark yellow powder (48 mg, 0.07 mmol, 63%).
Halogen exchange: When a mixture of [(1H-benzimidazolylidene)IrCp*I2] and [(1H-benzimidazolylidene)IrCp*ICl] was obtained, the obtained mixture was dissolved in acetone (66 mL/mmol compound) to which excess NaI (approx. 3.0 eq.) was added. The resulting mixture was stirred for 72h at RT. Volatiles were removed in vacuo to yield a yellow residue, which was extracted in DCM (240 mL/mmol compound). Evaporation of the extract yielded [(1H-benzimidazolylidene)IrCp*I2] as a yellow powder.
Alternative protocol 2: FeCl3 (49 mg, 0.30 mmol, 1.5 eq.) and NaI (90 mg, 0.60 mmol, 3.0 eq.) were dissolved in acetone (30 mL) to provide a black suspension. Immediately afterwards, a solution of [(2-azidophenylisonitrile)IrCp*I2] (147 mg, 0.20 mmol, 1.0 eq.) in DCM (6 mL) was added to the black suspension and the resulting mixture was stirred for 20h at RT. Volatiles (including iodine) were removed in vacuo to provide a very dark red residue, which was extracted in DCM (80 mL) under atmospheric conditions. The extract was subsequently washed with a solution of Na2S2O3 (100 mL, 20% in H2O), a solution of NaHCO3 (100 mL, saturated solution in H2O) and brine (100 mL). The resulting orange solution was dried over Na2SO4. After evaporation, [(1H-benzimidazolylidene)IrCp*I2] was obtained as a dark yellow powder (96 mg, 0.14 mmol, 69%).
(κ 2 -C,N-(acetimidoyl)-benzimidazolylidene) (1,2,3,4,5-pentamethylcyclopentadienyl) iridium(III) monoiodide (8)
Alternative protocol 1 / Control reaction 1: A red solution of FeCl3 (28 mg, 0.17 mmol, 1.9 eq.) in MeCN (6 mL) was added to a colourless solution of NaI (137 mg, 0.91 mmol, 10.1 eq.) in MeCN (6 mL). The resulting black mixture was added to an orange solution of [(1H-benzimidazolylidene)IrCp*I2] (63 mg, 0.09 mmol, 1.0 eq.) in DCM (3 mL). The resulting black mixture was stirred for 48h at RT. Volatiles (including iodine) were removed in vacuo to provide a black residue, which was extracted with DCM (35 mL) under atmospheric conditions. The extract was subsequently washed with a solution of Na2S2O3 (50 mL, 20% in H2O) and NaHCO3 (50 mL, saturated solution in H2O). The resulting yellow organic layer was dried over Na2SO4. After evaporation and washing with CHCl3 (2.5 mL), [(κ 2 -C,N-(acetimidoyl)-benzimidazolylidene)IrCp*I] was obtained as a yellow powder (41 mg, 0.07 mmol, 74%).
Alternative protocol 2 / Control reaction 2: [(1H-benzimidazolylidene)IrCp*I2] (6.5 mg, 0.0093 mmol, 1.2 eq.) was suspended in MeCN (2 mL) and refluxed for 5d. The resulting yellow solution was allowed to cool to RT and evaporated to provide [(κ 2 -C,N-1-(acetimino)benzimidazolylidene) IrCp*I2] as an oily orange-yellow solid, which then was dissolved in THF (3.9 mL) and cooled to -78 °C. A solution of DBU (0.1 mL of a 0.08M solution in THF, 1.0 eq.) in THF (0.1 mL) was added dropwise. The resulting yellow solution was allowed to warm to RT and was stirred for 60 min. Evaporation provided a yellow solid, which was washed with CHCl3 (0.5 mL) to provide [(κ 2 -C,N-(acetimidoyl)-benzimidazolylidene)IrCp*I] as a light yellow powder (1.5 mg, 0.0026 mmol, 32%).
Control reaction 3: [(2-azidophenylisonitrile)IrCp*I2] (90 mg, 0.12 mmol, 1.0 eq.) and NaI (190 mg, 1.27 mmol, 10.6 eq.) were dissolved in MeCN (13 mL) to provide a brown suspension. A red solution of FeCl3 (36 mg, 0.22 mmol, 1.8 eq.) in MeCN (12 mL) was added to provide a very dark brown mixture which was stirred for 49h at RT. Volatiles (including iodine) were removed in vacuo to provide a black solid, which was extracted in DCM (2 x 30 mL) under atmospheric conditions. The extract was subsequently washed with a solution of Na2S2O3 (60 mL, 20% in H2O) and NaHCO3 (60 mL, saturated solution in H2O). The resulting orange solution was dried over Na2SO4 and evaporated to provide an orange solid, which was washed with CHCl3 (10 mL Bis ((1,2,3,4 ,5-pentamethylcyclopentadienyl) iridium(III)) (μ-hydrido) di(μ-κ 2 -C,N-1H-benzimidazolylidene) monochloride (9) Alternative protocol 1 / Control reaction 1: [(1H-benzimidazolylidene)IrCp*Cl2] (6.5 mg, 0.01 mmol, 1.0 eq.) was suspended in MeOH (1 mL) to provide an orange mixture, to which zinc dust (2 mg, 0.03 mmol, 3 eq.) and H2O (0.01 mL) were added. The mixture was stirred at reflux for 7d to provide an orange/red solution, which was allowed to cool to RT and was evaporated to provide a red solid. Under atmospheric conditions, the solid was extracted into CD2Cl2 (3.0 mL), after which evaporation provided μ-κ 2 -C,N-1H-benzimidazolylidene)2Ir2Cp*2(μ-H)Cl] as a red solid (quant.).
Control reaction 2: [(2-azidophenylisonitrile)IrCp*I2] (65 mg, 0.09 mmol, 1.0 eq.) was suspended in MeOH (20 mL) to provide an orange mixture, which was added over NH4Cl (13 mg, 0.24 mmol, 2.7 eq.) and zinc dust (10 mg, 0.15 mmol, 1.7 eq.). H2O (0.2 mL) was added and the suspension was stirred at reflux for 7d to provide a brown solution, which was allowed to cool to RT and was evaporated. Under atmospheric conditions, the brown solid was extracted in DCM (10 mL + 5 mL) and the combined extracts were evaporated to provide an orange powder, which was washed with Et2O (15 mL) and pentane (15 mL). The powder was dissolved in DCM (20 mL) and washed with H2O (20 mL). Evaporation of the organic layer provided a red powder. 1 H-NMR analysis showed no [(μ-κ 2 -C,N-1H-benzimidazolylidene)2Ir2Cp*2(μ-H)X] formation.
Control reaction 3: [(1H-benzimidazolylidene)IrCp*Cl2] (6.5 mg, 0.01 mmol, 1.0 eq.) was suspended in MeOH (1 mL) to provide an orange mixture, to which H2O (0.01 mL) was added. The mixture was stirred at reflux for 7d to provide an orange solution, which was allowed to cool to RT and evaporated to yield a red solid. 1 H-NMR analysis showed no [(μ-κ 2 -C,N-1H-benzimidazolylidene)2Ir2Cp*2(μ-H)Cl] formation. (3-benzimidazolyl) (1,2,3,4 
Attempted synthesis

,5-pentamethylcyclopentadienyl) iridium(III) dichloride
To a white suspension of benzimidazole (20 mg, 0.17 mmol, 3.4 eq.) in DCM (5 mL) was added [IrCp*Cl2]2 (38 mg, 0.05 mmol, 1.0 eq.) to provide a yellow suspension, which was stirred for 2 days at RT. Evaporation yielded a yellow solid, which was washed with Et2O (3 x 2 mL) to provide a white-yellow solid (22 mg, 0.04 mmol, 44%). The extremely low solubility of the product prevented further identification. ((1,2,3,4 ,5-pentamethylcyclopentadienyl) rhodium(III)) (μ-hydrido) di(μ-κ 2 -C,N-1H-benzimidazolylidene) monochloride [(2-azidophenylisonitrile) RhCp*Cl2] (56 mg, 0.12 mmol, 1.0 eq.), NH4Cl (26.2 mg, 0.49 mmol, 4.1 eq.) and zinc dust (20 mg, 0.30 mmol, 2.5 eq.) were combined in MeOH (15 mL) to give a red suspension, to which H2O (0.12 mL) was added. The resulting mixture was stirred at reflux for 164 hr to provide a red solution, which was allowed to cool to RT and was evaporated. The resulting red powder was washed with pentane (1 x 10 mL, 2 x 6 mL) and Et2O (2 x 10 mL). Under atmospheric conditions, the residue was dissolved in DCM (60 mL) and washed with H2O (3 x 60 mL, 1 x 40 mL). The organic layer was dried and evaporated to provide a red solid. 1 H-NMR analysis showed no bis((1,2,3,4,5-pentamethylcyclopentadienyl) rhodium(III)) (μ-hydrido) di(μ-κ 2 -C,N-1H-benzimidazolylidene) monochloride) formation but a mixture of [(1H-benzimidazolylidene)RhCp*Cl2] and unidentified side-products.
Attempted synthesis bis
Attempted synthesis bis((1-methyl-4-isopropyl-benzene) ruthenium(II)) (μ-hydrido) di(μ-κ 2 -C,N-1H-benzimidazolylidene) monochloride
Protocol 1: [Ru(p-cymene)(2-azidophenylisonitrile)Cl2] (74 mg, 0.16 mmol, 1.0 eq.), NH4Cl (35 mg, 0.64 mmol, 4.0 eq.) and zinc dust (26 mg, 0.40 mmol, 2.5 eq.) were combined in MeOH (16 mL) to provide a yellow/brown suspension to which H2O (0.17 mL) was added. The mixture was stirred at reflux for 165 hr to provide a black suspension, which was allowed to cool to RT and was evaporated. Washing with Et2O (3 x 10 mL) provided a black powder (0% bis((1-methyl-4-isopropyl-benzene) ruthenium(II)) (μ-hydrido) di(μ-κ 2 -C,N-1H-benzimidazolylidene) monochloride). 1 H-NMR analysis revealed decomposition.
Protocol 2: [Ru(p-cymene)(2-azidophenylisonitrile)Cl2] (78 mg, 0.17 mmol, 1.0 eq.), NH4Cl (36 mg, 0.66 mmol, 3.9 eq.) and zinc dust (26 mg, 0.40 mmol, 2.4 eq.) were combined in MeOH (17 mL) to provide a yellow/brown suspension to which H2O (0.17 mL) was added. The mixture was stirred at RT for 164 hr to provide a black suspension, which was allowed to cool to RT and was evaporated. Washing with Et2O (3 x 10 mL) provided a black powder (0% bis((1-methyl-4-isopropyl-benzene) ruthenium(II)) (μ-hydrido) di(μ-κ 2 -C,N-1H-benzimidazolylidene) monochloride; partial formation of (1H-benzimidazolylidene) Ru(II)(p-cymene)Cl2; 7 HRMS (ESI-Q-TOF): calcd. for C17H22ClN2Ru: 391.0515; found: 391.0345).
NMR-spectra
General considerations
NMR spectra were recorded on Bruker Avance 400 ( 1 H, 400.13 MHz; 13 C{ 1 H}, 100.61 MHz, room temperature) or a Bruker Avance 500 ( 1 H, 500.23 MHz; 13 C{ 1 H}, 125.78 MHz; room temperature) . Chemical shifts are reported in ppm downfield from tetramethylsilane. 1 H-spectra were internally referenced to residual solvent resonances: CDCl3 (δ 7.26) and CD2Cl2 (δ 5.32). 13 C-spectra were internally referenced to residual solvent resonances: CDCl3 (δ 77.16) and CD2Cl2 (δ 53.84). 
Crystal structure determinations
The single-crystal X-ray diffraction studies of 3, 4 and 6 were carried out on a Bruker-Nonius at 123(2) K using Mo-Kα radiation (λ = 0.71073 Å). Direct Methods or heavy atom methods (SHELXS-97) 8 were used for structure solution and refinement was carried out using SHELXL-2013 (full-matrix least-squares on F 2 ). 9 Hydrogen atoms were localized by difference electron density determination and refined using a riding model (H(N) free). Semi-empirical absorption corrections were applied. For 3 an extinction correction was applied. The single-crystal X-ray diffraction study of 9 was performed on a Bruker Kappa ApexII diffractometer with sealed tube and Triumph monochromator (λ = 0.71073 Å) at a temperature of 150(2) K up to a resolution of (sin λ/θ)max = 0.61 Å-1. The Eval15 software 10 was used for the intensity integration. For the prediction of reflection profiles a rather large isotropic mosaicity of 1.0 ° was used. A numerical absorption correction and scaling was performed with SADABS 11 (correction range 0.51-0.85). A total of 24638 reflections was measured, 13828 reflections were unique (Rint = 0.028) leading to an overall completeness of 94.4%. 10816 reflections were observed [I>2σ(I)]. The structure was solved with Patterson superposition methods using SHELXT. 12 Structure refinement was performed with SHELXL-2018 9 on F 2 of all reflections. Two of the four independent solvent molecules were refined with disorder models. In these disorder components, three C atoms were refined isotropically. All other non-hydrogen atoms were refined freely with anisotropic displacement parameters. The hydrogen atoms were introduced in calculated positions. The Ir-H hydrogen atoms were kept fixed at the calculated position. All other hydrogen atoms were refined with a riding model. 918 Parameters were refined with 202 restraints (concerning distances, angles and displacement parameters in the CH2Cl2 solvent). R1/wR2 [I > 2σ(I)]: 0.0370 / 0.0906. R1/wR2 [all refl.]: 0.0549 / 0.0983. S = 1.022. Residual electron density between -2.27 and 1.83 e/Å3. Geometry calculations and checking for higher symmetry was performed with the PLATON program. 13 Figure S31 . Molecular structure of 3 (solvent omitted for clarity, displacement parameters are drawn at 50% probability level) Figure S32 . Molecular structure of 4 (displacement parameters are drawn at 50% probability level) Figure S34 . Molecular structure of 9 (only one of two independent molecules is shown. Displacement parameters are drawn at 50% probability level). 
DFT calculations Computational Procedures
Density functional calculations were performed at the BP86/ZORA/Grimme-D3/TZ2P level of theory 14 using Amsterdam Density Functional (ADF) 15 2013.01 (geometry optimizations, QTAIM 16 ) and 2016.102 (ETS-NOCV 17 ). The nature of each stationary point was confirmed by frequency calculations.
Iridium-carbene bond analysis (ETS-NOCV)
Table S1. ETS-NOCV results (BP86/ZORA/Grimme-D3/TZ2P; kcal mol -1 ).
4|| 6
ΔEtotal -67. 
